Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
This study is to compare the efficacy and safety of defibrotide prophylaxis in addition to best supportive care versus best supportive care alone in the prevention of hepatic veno- occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or very high risk of developing VOD.
- Veno-occlusive Disease
- Eligible Ages
- Over 1 Month
- Eligible Genders
- Accepts Healthy Volunteers
- Patient must be above the age of 1 month as of the start date of study treatment.
- Patient must be scheduled to undergo allogeneic hematopoietic stem cell transplant (HSCT) (adults or pediatric patients) or autologous HSCT (pediatric patients only) and be at high risk or very high risk of developing veno-occlusive disease (VOD).
- Female patients (and female partners of male patients) of childbearing potential who are sexually active must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 1 week after the last dose of defibrotide.
- Adult patients must be able to understand and sign a written informed consent. For minor patients, the parent/legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
- Patient has hemodynamic instability within 24 hours before the start of study treatment.
- Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment.
- Patient used any medication that increases the risk of bleeding within 24 hours before the start of study treatment.
- Patient is using or plans to use an investigational agent for the prevention or treatment of VOD.
- Patient, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Patient or parent/legal guardian or representative has a psychiatric illness that would prevent the patient or parent/legal guardian or representative from giving informed consent and/or assent.
- Patient has a serious active disease or co-morbid medical condition, as judged by the investigator, which would interfere with the conduct of this study.
- Patient is pregnant or lactating and does not agree to stop breastfeeding.
- Patient has a known history of hypersensitivity to defibrotide or any of the excipients.
- Patient or parent/legal guardian or representative lacks the full mental capacity to understand and sign a written informed consent.
- Patient is receiving or plans to receive other investigational therapy during study.
- Phase 3
- Study Type
- Intervention Model
- Parallel Assignment
- Primary Purpose
- None (Open Label)
|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT||
Best Supportive Care
|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable||
- Jazz Pharmaceuticals
Study ContactClinical Trial Information Desk